Status:
COMPLETED
Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial
Lead Sponsor:
PharmEvo Pvt Ltd
Conditions:
Essential Hypertension
Eligibility:
All Genders
18-70 years
Brief Summary
To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) after 8 weeks of th...
Detailed Description
Avsar in tablet form which contains two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium an...
Eligibility Criteria
Inclusion
- Patient whose BP is \>139/89mmHg and on monotherapy with minimum last 30 days
- Male or female aged (18 years - 70 Years)
- Signed informed consent
Exclusion
- Secondary Hypertension
- Pregnant or Lactating mother
- Hypersensitivity to any active ingredient
- Peripheral artery disease
- Hepatic disease or biliary tract obstruction
- Chronic kidney disease
Key Trial Info
Start Date :
February 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 5 2018
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT03371797
Start Date
February 20 2018
End Date
November 5 2018
Last Update
November 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medicell
Karachi, Sindh, Pakistan, 75290